Peter Hersey
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
Papers in
- Immunology 155
- Immunotherapy and Immune Responses 110
- Immune Cell Function and Interaction 33
- Oncology 144
- CAR-T cell therapy research 51
- Cancer Immunotherapy and Biomarkers 49
- Cutaneous Melanoma Detection and Management 48
- Co-authors
- Xu Dong Zhang (79 shared papers)John F. Thompson (20 shared papers)William H. McCarthy (31 shared papers)Wayne D. Thomas (9 shared papers)Richard Scolyer (24 shared papers)Susan K. H. Gillespie (11 shared papers)Richard F. Kefford (16 shared papers)Stuart J. Gallagher (30 shared papers)
- Journals
- International Journal of Cancer (28 papers)Clinical Cancer Research (17 papers)British Journal of Cancer (14 papers)Nature Communications (13 papers)Cancer Immunology Immunotherapy (12 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Peter Hersey
384 papers receiving 50.1k citations
Peter Hersey's Hit Papers
Peers
Comparison fields: 5 of 182
- Oncology 21.6k
- Cancer Research 9.5k
- Immunology 11.3k
- Molecular Biology 25.1k
- Pathology and Forensic Medicine 3.1k
Countries citing papers authored by Peter Hersey
This map shows the geographic impact of Peter Hersey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hersey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hersey more than expected).
Fields of papers citing papers by Peter Hersey
This network shows the impact of papers produced by Peter Hersey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hersey. The network helps show where Peter Hersey may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Hersey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 390 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Hit paper breakdown → | 2013 | 2928 |
| 2 | Genomic Classification of Cutaneous Melanoma Hit paper breakdown → | 2015 | 2509 |
| 3 | The repertoire of mutational signatures in human cancer Hit paper breakdown → | 2020 | 2339 |
| 4 | Pan-cancer analysis of whole genomes Hit paper breakdown → | 2020 | 2109 |
| 5 | Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib Hit paper breakdown → | 2012 | 1823 |
| 6 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Hit paper breakdown → | 2012 | 1820 |
| 7 | Comprehensive Characterization of Cancer Driver Genes and Mutations Hit paper breakdown → | 2018 | 1714 |
| 8 | Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation Hit paper breakdown → | 2018 | 1617 |
| 9 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1225 |
| 10 | Whole-genome landscapes of major melanoma subtypes Hit paper breakdown → | 2017 | 1099 |
| 11 | Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma Hit paper breakdown → | 2017 | 1011 |
| 12 | Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Hit paper breakdown → | 2016 | 905 |
| 13 | Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas Hit paper breakdown → | 2018 | 810 |
| 14 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Hit paper breakdown → | 2019 | 742 |
| 15 | The evolutionary history of 2,658 cancers Hit paper breakdown → | 2020 | 705 |
| 16 | Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab Hit paper breakdown → | 2016 | 605 |
| 17 | 2011 | 569 | |
| 18 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma Hit paper breakdown → | 2018 | 569 |
| 19 | Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma Hit paper breakdown → | 2016 | 550 |
| 20 | Patterns of somatic structural variation in human cancer genomes Hit paper breakdown → | 2020 | 550 |
About Peter Hersey
Peter Hersey is a scholar working on Immunology, Oncology, Molecular Biology, Cancer Research and Cell Biology, having authored 390 papers that have together received 51.5k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (110 papers), Melanoma and MAPK Pathways (58 papers), CAR-T cell therapy research (51 papers), Cancer Immunotherapy and Biomarkers (49 papers), Cutaneous Melanoma Detection and Management (48 papers), Cell death mechanisms and regulation (46 papers), Immune Cell Function and Interaction (33 papers) and Monoclonal and Polyclonal Antibodies Research (30 papers). The work is most often cited by research in Oncology (21.6k citations), Cancer Research (9.5k citations), Immunology (11.3k citations), Molecular Biology (25.1k citations) and Pathology and Forensic Medicine (3.1k citations). Peter Hersey has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Xu Dong Zhang, John F. Thompson, William H. McCarthy, Wayne D. Thomas, Richard Scolyer, Susan K. H. Gillespie, Richard F. Kefford, Stuart J. Gallagher, Christian P. Gray and Chen Chen Jiang. Their work appears in journals such as International Journal of Cancer, Clinical Cancer Research, British Journal of Cancer, Nature Communications and Cancer Immunology Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.